Diovan 160 mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
58	肥大型心筋症	1

58. 肥大型心筋症

---

臨床試験数 : 119 /  薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002283-16-DK (EUCTR)	08/03/2016	16/12/2015	An international study of the effect of Valsartan in hypertrophic cardiomyopathy.	Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM - VANISH	Hypertrophic cardiomyopathy MedDRA version: 19.0;Level: LLT;Classification code 10020204;Term: HOCM Hypertrophic obstructive cardiomyopathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Diovan 40 mg INN or Proposed INN: VALSARTAN Other descriptive name: Diovan Trade Name: Diovan 80 mg INN or Proposed INN: VALSARTAN Other descriptive name: Diovan Trade Name: Diovan 160 mg INN or Proposed INN: VALSARTAN	National Heart, Lung, and Blood Institute / National Institutes of Health	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 2	Denmark